KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Net Income towards Common Stockholders: 2017-2025

Historic Net Income towards Common Stockholders for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to $18.1 million.

  • Amneal Pharmaceuticals' Net Income towards Common Stockholders rose 54.22% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.6 million, marking a year-over-year increase of 137.94%. This contributed to the annual value of -$116.9 million for FY2024, which is 39.16% down from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Net Income towards Common Stockholders stood at $18.1 million, which was down 49.08% from $35.6 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at $35.6 million for Q2 2025, and its period low was -$120.8 million during Q2 2022.
  • In the last 3 years, Amneal Pharmaceuticals' Net Income towards Common Stockholders had a median value of $11.8 million in 2024 and averaged -$7.2 million.
  • The largest annual percentage gain for Amneal Pharmaceuticals' Net Income towards Common Stockholders in the last 5 years was 460.06% (2023), contrasted with its biggest fall of 2,176.69% (2023).
  • Over the past 5 years, Amneal Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at -$6.4 million in 2021, then skyrocketed by 32.05% to -$4.3 million in 2022, then plummeted by 2,176.69% to -$98.6 million in 2023, then surged by 78.94% to -$20.8 million in 2024, then spiked by 54.22% to $18.1 million in 2025.
  • Its Net Income towards Common Stockholders stands at $18.1 million for Q3 2025, versus $35.6 million for Q2 2025 and $24.6 million for Q1 2025.